Approach to selection of first-line treatment for advanced kidney cancer

During this online interview, the approach to selection of first-line treatment for patients with metastatic renal cell carcinoma (RCC) was discussed.  Traditionally, the selection of initial treatments was very straightforward, and patients were treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, (TKIs) such as sunitinib and pazopanib. Over the past 2 years, decisions […]

read more

Neoadjuvant nivolumab for patients with non-metastatic high risk kidney cancer

A recent phase 1 trial showed that treatment with nivolumab before surgery (neoadjuvant treatment) was tolerable in patients with high-risk clear cell renal cell carcinoma (RCC) that had not spread. These results were presented at the 21st Annual Meeting of the Society of Urologic Oncology (SUO). The study was a phase 1 trial that looked […]

read more

Active surveillance is a safe strategy for small renal masses suspected to be cancer

A recent study published at the 21st Annual Meeting of the Society of Urologic Oncology (SUO) concluded that active surveillance is a safe and long lasting management strategy for some patients with small renal masses, which are suspected to be stage T1a (≤4 cm) renal cell carcinoma (RCC). The researchers found the cancer-specific survival rate […]

read more

Psychosocial effects of kidney cancer

As with most cancers, the psychosocial effects of renal cell carcinoma (RCC) are profound. Around 20% of patients experience depression and 30% experience anxiety due to various reasons, such as treatment side effects, disease-related changes, finances and coping strategies. Not only are these symptoms distressing, they can also affect survival. This was described using two […]

read more

UK first to approve coronavirus vaccine

The UK has become the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine, paving the way for mass vaccination. Britain’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), says the vaccine, which offers up to 95% protection against COVID-19, is safe to be rolled out throughout the UK. The first […]

read more

Get cancer symptoms checked out

The NHS has launched a programme to encourage patients to have any potential cancer symptoms checked out: NHS staff have worked hard to ensure that cancer services have been maintained throughout the pandemic. Between March and September, over 1 million people were referred by their GP with suspected cancer, and over 291,000 cancer treatments were […]

read more

Liquid biopsies in kidney cancer

In this review, the key substances found in the blood, such as circulating free (cf)DNA, cfRNA, proteins, and exosomes (sacs containing proteins, DNA and/or RNA), which may act as biomarkers for monitoring the progression of clear cell renal cell carcinoma (ccRCC) are discussed. Limitations of these techniques and promising technologies that could help with the […]

read more

HIF2α inhibitor provides significant clinical benefit in patients with VHL kidney cancer

One of the major breakthroughs this year the hypoxia-inducible factor (HIF)-2α inhibitor: MK6482 for von Hippel-Lindau (VHL) disease–related clear cell renal cell carcinoma (RCC). VHL disease is a hereditary disease that affects many organs of the body, such as the eyes, brain, spine, pancreas, kidneys and lymphatic system. It is caused by a mutation in […]

read more

NHS to trial innovative cancer blood test

The NHS is trialling an innovative new blood test that may be able to detect more than 50 types of cancer. The Galleri blood test, developed by a company called GRAIL, will be piloted with 165,000 patients. Prior research on patients with signs of cancer has already found that the test, which checks for molecular […]

read more

Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Texas in the USA talks about managing adverse events to immunotherapy and targeted therapy combinations. There are more adverse events from any type of combination treatment compared to single treatments, especially immune adverse events. Nivolumab alone is very well tolerated and quite easy […]

read more
Showing 21 to 30 of 268 results
  TOP